Happy to share news of my upcoming promotion to Associate Professor of Medicine at @ou.edu starting this July. Grateful to my mentors and colleagues who helped make it happen, including those who wrote letters of support for my promotion.

Evaluation of a Remote Therapeutic Monitoring (RTM) Device and Integrated Care Platform in Outpatient Parenteral Antimicrobial Therapy (OPAT) ✅ Just Accepted 🔗 https://bit.ly/4spq9ts

Out now in @cidjournal.bsky.social my first ever investigator-initiated funded study - A pilot trial evaluating IV Ensure, a remote therapeutic monitoring device in OPAT! #IDSky #OPAT Open access thanks to @ou.edu libraries so check it out! Key highlights in 🧵 academic.oup.com/cid/advance-...

Come train with us! We have two open spots for ID fellowship at @ou.edu Great clinical exposure, academic tracks (TxID, healthcare admin/hospital epi, trop med/global health, CCM fellowship), 12-credit certificates covered by the program. #IDSky #TxID #MedEd medicine.ouhsc.edu/academic-dep...

Also out now in American Journal of Medical Sciences, our review of infectious complications of CAR T and BsAb, led by @ou.edu ID fellow Bradley Dye, a good primer for trainees and faculty alike! #TxID #IDSky www.amjmedsci.org/article/S000...

Out now in @ichejournal.bsky.social , with @ritawilson.bsky.social and others, our report on the blood culture bottle shortage last year affecting the diagnostic yield in febrile neutropenia @ou.edu #TxID #IDSky doi.org/10.1017/ice....

@bryanpwhite.bsky.social et al: In a cohort (n=127) of OPAT patients on daptomycin 7.4 mg/kg for an average of 37 days, the rate of CK elevation was 11.8% at a median of 13 days (IQR 9-16) supporting weekly lab monitoring on daptomycin for OPAT. doi.org/10.1017/ash....

This study offers real-world data evaluating the ePlex BCID-FP rapid identification system for yeast and found it was less sensitive than previously reported and infrequently led to de-escalation of antifungals doi.org/10.1093/jaca... @josephsassinemd.bsky.social #JACAMRNews #IDSKy

ID fellowship applicants, make sure to check out our program @ou.edu: 2 year clinical program - 3 tracks (TxID, hosp epi, trop med) - Path for crit care fellowship - 12 credit certificates in year 2 #TxID #IDSky #MedEd medicine.ouhsc.edu/academic-dep...

Out now in @jac-amr.bsky.social, our real world analysis of BCID fungal panel for diagnosis of fungemia, led by the great Emily Siegrist - Sensitivity of 94%, lower than anticipated @bryanpwhite.bsky.social @ritawilson.bsky.social #IDSky academic.oup.com/jacamr/artic...

And part 2 is out now: How to prevent travel-related infections in the transplant recipient, check it out! @ritawilson.bsky.social @andhen25.bsky.social #IDSky #TxID journals.sagepub.com/doi/full/10....

Invasive fusariosis after CAR T is rare but can be consequential. Here’s our case of cutaneous fusariosis after CD19 CAR T, with @ritawilson.bsky.social @ouholter.bsky.social and others, out in @asm.org Case Reports! #TxID journals.asm.org/doi/10.1128/...

Had a great time in Syracuse presenting Medicine Grand Rounds earlier today on Infections after CAR T at SUNY Upstate and meeting some great ID colleagues there! #TxID

Excited to launch new tracks in our 2-year ID fellowship program @ou.edu starting July 2025: TxID, Hospital epi/healthcare admin, Trop Med/Global Health, ID/Crit Care. Tracks come with option for 12-credit certificates, covered by the program: medicine.ouhsc.edu/academic-dep... 🧵 #IDSky #TxID

How to prevent infections in the increasingly immunocompromised traveler? Part 1 (non-transplant) is out now! Stay tuned for part 2! @ritawilson.bsky.social @andhen25.bsky.social @ou.edu #IDSky #TxID journals.sagepub.com/doi/10.1177/...

Out now, everything you need to know, that is known and not known, about herpesviruses after CAR T and BsAb, in our review with Dr Emily Siegrist and Dr Roy Chemaly! @mdanderson.bsky.social @ou.edu #IDSky #TxID www.mdpi.com/1999-4915/17...

Spoke to @koconews.bsky.social about norovirus, clinical presentation and preventive measures #IDSky www.koco.com/article/okla...

T-SPOT.TB performs much better in many immunocompromised populations IMO, but historically was logistically more difficult from CA due to time-sensitive FedEx of samples to Memphis which failed a lot with winter storms. Less an issue now that Quest bought T-SPOT.

T-SPOT resulted in - fewer indeterminate results (than QFT) - more “actionable” results (than QFT) in certain immunocompromised populations #TBSky

Out now in @thetxidjournal.bsky.social! T-SPOT.TB is more likely to produce actionable results than QFT-TB in patients with cancer being screened for latent TB. #TxID #IDSky onlinelibrary.wiley.com/doi/10.1111/...

A retrospective cohort study of Gram-negative BSIs in ICU shows fever, lack of source control and time to repeat follow-up blood culture (FUBC) as risk factors for repeat positive FUBC: https://doi.org/10.1093/jacamr/dlae144 #JACAMRNews @bryanpwhite.bsky.social

Special theme issue in @cmijournal.bsky.social - Infections in immunocompromised hosts, edited by Dr Roy Chemaly, with a series of high yield #TxID reviews, including our review of herpesviruses after allogeneic HCT #IDSky www.clinicalmicrobiologyandinfection.com/article/S119...

Recently spoke with Health IT News about the results of our innovative trial of remote therapeutic monitoring in OPAT, how RTM helped us reduce infection-related readmissions and improve patient adherence to IV ABx #IDSky #OPAT @ou.edu www.healthcareitnews.com/news/remote-...

Check out our most recent work - A large database analysis of viral and fungal infections after CAR T cell therapy, published at @cmijournal.bsky.social, with @andhen25.bsky.social #IDSky #TxID www.clinicalmicrobiologyandinfection.com/article/S119...

First post on #IDSky We have an ID fellowship opening at the University of Oklahoma @ou.edu, starting July 2025. Two-year program, with great exposure to HIV, transplant ID and surgical infections, and above all, great people to train with! DM me for details! medicine.ouhsc.edu/academic-dep...